We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04172597
Recruitment Status : Terminated (Strategic business decision (unrelated to safety))
First Posted : November 21, 2019
Last Update Posted : June 14, 2022
Sponsor:
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.

Condition or disease Intervention/treatment Phase
Breast Cancer Colorectal Cancer Solid Tumor Glioblastome Multiforme Drug: Poziotinib Hydrochloride Drug: Loperamide Phase 2

Detailed Description:

The Screening period (Day -30 to Day 1) begins 30 days prior to poziotinib treatment on Day 1 of Cycle 1. Patients must meet all Inclusion/Exclusion Criteria and provide informed written consent prior to study procedures.

The duration of each treatment cycle is 28 days. There will be five patient cohorts. Eligible patients will be enrolled into cohorts concurrently based on EGFR or HER2 exon 20 mutation status.

  • Cohort 1: HER2-positive or HER2-negative breast cancer (BC) with a HER2 activating mutation.
  • Cohort 2: Colorectal cancer (CRC) with a HER2 activating mutation.
  • Cohort 3: Any solid cancer, except non-small cell lung cancer (NSCLC), BC, or CRC with a HER2 activating mutation.
  • Cohort 4: Glioblastome multiforma (GBM) with an EGFR activating mutation.
  • Cohort 5: Any solid cancer, except NSCLC or GBM with an EGFR activating mutation.

All patients will be treated daily for up to 24 months unless there is disease progression, death, intolerable adverse events (AEs), or another protocol-specified reason for patient withdrawal. After treatment discontinuation, patients will be contacted every 3 months for up to 2 years after the first dose of poziotinib to assess survival.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Each treatment cycle is 28 calendar days in duration. This is a basket study with five distinct cohorts. Eligible patients will be enrolled into the five cohorts concurrently based on tumor type and mutational status.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
Actual Study Start Date : December 23, 2019
Actual Primary Completion Date : March 29, 2022
Actual Study Completion Date : March 29, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Loperamide

Arm Intervention/treatment
Experimental: Cohort 1
Patients with HER2-positive or HER2-negative BC with a HER2 activating mutation will receive poziotinib 8 milligrams (mg), orally, twice daily (BID) starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Drug: Poziotinib Hydrochloride
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Drug: Loperamide
Loperamide as prescribed by the physician.

Experimental: Cohort 2
Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Drug: Poziotinib Hydrochloride
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Drug: Loperamide
Loperamide as prescribed by the physician.

Experimental: Cohort 3
Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Drug: Poziotinib Hydrochloride
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Drug: Loperamide
Loperamide as prescribed by the physician.

Experimental: Cohort 4
Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Drug: Poziotinib Hydrochloride
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Drug: Loperamide
Loperamide as prescribed by the physician.

Experimental: Cohort 5
Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Drug: Poziotinib Hydrochloride
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Drug: Loperamide
Loperamide as prescribed by the physician.




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 24 months ]
    Proportion of participants whose best overall response is confirmed complete response (CR) or partial response (PR).


Secondary Outcome Measures :
  1. Duration of Response (DoR) [ Time Frame: 24 months ]
    Time from the first CR or PR until progressive disease or death.

  2. Disease Control Rate (DCR) [ Time Frame: 24 months ]
    Proportion of participants whose best overall response is CR, PR, or stable disease (SD).

  3. Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Form first dose of study drug administration until 30 (±5) days after the last dose of study drug (Up to approximately 25 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Patients must be at least 18 years old.
  2. Patients must have histologic or cytologic evidence of a malignant solid cancer that is either advanced or metastatic there must be no available therapy known to confer a reasonable likelihood of clinical benefit.
  3. Patients with BC must have a HER2 activating mutation determined by next-generation sequencing (NGS) performed on either tumor or plasma samples and:

    • Immunohistochemistry (IHC) HER2-positive BC that has progressed on trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1) in the metastatic setting, unless there is recurrent disease within 12 months of adjuvant or neoadjuvant treatment.
    • IHC HER2-negative, estrogen receptor/progesterone receptor (ER/PR)-positive BC that has progressed on or after appropriate first-line endocrine therapy in the metastatic setting.
    • IHC HER2-negative, ER/PR-negative BC that has progressed after first-line treatment (any standard chemotherapy-based regimen) in the metastatic setting.
  4. Patients with microsatellite instability-high (MSI-H) CRC must have had appropriate checkpoint inhibitor-based therapy.
  5. Patient's tumor must be positive for an EGFR or HER2 mutation based on DNA testing of either tumor tissue or plasma samples. Patients with documented EGFR or HER2 mutations may be identified by local testing from participating sites using next generation sequencing tests. Patient has a solid tumor with at least one of the listed activating mutations:

    • Cohorts 1-3: HER2 Activating Mutations (at least one of the following) Furin-Like/Extracellular. S310F/Y Transmembrane. I655V, V659E, R678Q, V697L Kinase Domain. Exon 20 insertion, T733I, L755X, I767M, D769X, V773M, V777X, L786V, V842I, T862I, L869R.
    • Cohorts 4-5: EGFR Activating Mutations (at least one of the following) Extracellular & Transmembrane: EGFRvIII, R108K, R222C, A289T, P596L, G598V Kinase Domain: Exon 20 insertion, E709X, E709_T710del insD, L718X, G719X, I740_K745dupIPVAIK, I740_K745dup, V742I, L747X, E746_A750del, A750P, S768I, S768I/V769L, S768I/V774M, L833V, V769M, V774M, R831C, R831H, L858R, L861Q, A864V.
  6. Patients must have measurable disease.
  7. Patients with central nervous system (CNS) metastases must have stable CNS disease and no evidence of growth on imaging for at least 4 weeks following radiation or other locoregional ablative therapy. CNS symptoms must be stable with no requirement for anti-seizure medications and/or > 2 mg/day dexamethasone equivalent, except for patients with GBM (Cohort 4), in whom anti-seizure medications and/or up to 4 mg/day dexamethasone equivalent is allowed.
  8. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ -1.
  9. Patients must have adequate hematopoietic, renal, and liver functions.

Exclusion Criteria:

  1. Patient has an EGFR T790 mutation.
  2. Patient has breast or gastric cancer without eligible HER2 mutations (see Inclusion Criteria).
  3. Patients with GBM enrolled in Cohort 4 has been treated with an inhibitor of vascular endothelial growth factor (VEGF) inhibitor therapy (e.g., bevacizumab).
  4. Patient requires treatment with a medication that is a strong inhibitor or inducer of CYP3A4 or CYP2D6 or has been treated with such medications within 15 days of poziotinib treatment.
  5. Patient has ≥ Grade 2 skin disorders (rash), mucositis, or stomatitis within 15 days of poziotinib treatment.
  6. Patient has a gastrointenstinal disorder or malabsorption that precludes oral drug treatment.
  7. Patient has active liver or biliary tract disease (except for Gilbert's syndrome, asymptomatic biliary stones, liver metastasis, or stable chronic liver diseases).
  8. Patient has a history of drug-induced pancreatitis.
  9. Patient has a history of interstitial lung disease or pneumonitis.
  10. Patient has a history of congestive heart failure Class III/IV according to the New York Heart Association Functional Classification or a serious cardiac arrhythmia requiring treatment.
  11. Patient has a high risk of cardiac disease as determined by the Investigator. If patient is deemed to have a high cardiac risk, enrollment may be considered if an echocardiogram (ECHO) or multi-gated acquisition (MUGA) during Screening demonstrates a cardiac ejection fraction >= 50%.
  12. Patient has a QTc interval > 470 ms.
  13. Patient has a history of another malignancy within the 1 year prior to poziotinib treatment. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia, and melanoma in situ), organ-confined prostate cancer with no evidence of progressive disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04172597


Locations
Layout table for location information
United States, California
Pacific Shores Medical Group
Long Beach, California, United States, 90813
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
Investigators
Layout table for investigator information
Study Director: Jaba Kokhreidze, MD Spectrum Pharmaceuticals, Inc
Layout table for additonal information
Responsible Party: Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT04172597    
Other Study ID Numbers: SPI-POZ-203
First Posted: November 21, 2019    Key Record Dates
Last Update Posted: June 14, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Spectrum Pharmaceuticals, Inc:
EGFR activating mutations
HER2 activating mutations
HER2-positive breast cancer
HER2-negative breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Loperamide
Antidiarrheals
Gastrointestinal Agents